Management of benign skin lesions commonly affecting the face: Actinic keratosis, seborrheic keratosis, and rosacea

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 17, Issue 4, 2009, Pages 315-320

  Brodsky, Jacob ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Actinic keratosis; Rosacea; Seborrheic keratosis

Indexed keywords

AMINOLEVULINIC ACID; AZELAIC ACID; AZITHROMYCIN; CLINDAMYCIN; DICLOFENAC; DOXYCYCLINE; FLUOROURACIL; HYALURONIC ACID; IMIQUIMOD; LIQUID NITROGEN; METRONIDAZOLE; PIMECROLIMUS; PLACEBO; SULFONAMIDE; TACROLIMUS; TETRACYCLINE; TOPICAL AGENT; VITAMIN D;

ACTINIC KERATOSIS; CRUSTING; CRYING; CRYOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; EROSION; ERYTHEMA; HUMAN; LOW LEVEL LASER THERAPY; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; ROSACEA; SEBORRHEIC KERATOSIS; SIDE EFFECT; SKIN BIOPSY; SKIN DEFECT; SKIN MANIFESTATION; SKIN SURGERY; UNSPECIFIED SIDE EFFECT;

COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; FACIAL DERMATOSES; FEMALE; HUMANS; KERATOSIS, ACTINIC; KERATOSIS, SEBORRHEIC; LASER THERAPY; MALE; PHOTOCHEMOTHERAPY; PROGNOSIS; RISK ASSESSMENT; ROSACEA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 68949186257     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e32832d75e3     Document Type: Review

References (46)

1. Oppel T, Korting HC. Actinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol 2004; 17:67-76.
2. Schwartz RA, Bridges TM, Butani AK, etal. Actinic keratosis: an occupational and environmental disorder. J Eur Acad Dermatol Venereol 2008; 22:606-615.
3. Rossi R, Mori M, Lotti T. Actinic keratosis. IntJ Dermatol 2007; 46:895-904.
4. Kanellou P, Zaravinos A, Zioga M, et al. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. Cancer Lett 2008; 264:145-161.
5. Vasiljevic N, Hazard K, Dillner J, etal. Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. J Gen Virol 2008; 89 (Pt 10):2467-2474.
6. Rojas IG, Mart?́nez A, Brethauer U, et al. Actinic cheilitis: epithelial expression of COX-2 and its association with mast cell tryptase and PAR-2. Oral Oncol 2009; 45:284-290.
7. Ulrich M, Maltusch A, Rius-Diaz F, et al. Clinical applicability of in vivo reflectance confocal microscopy for the diagnosis of actinic keratoses. Dermatol Surg 2008; 34:610-619.
8. Horn M, Gerger A, Ahlgrimm-Siess V, etal. Discrimination of actinic keratoses from normal skin with reflectance mode confocal microscopy. Dermatol Surg 2008; 34:620-625.
9. Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol 2009; 145:203-205.
10. Jorizzo J, Weiss J, Furst K, etal. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol 2004; 140:813-816.
11. Zeichner JA, Stern DW, Uliasz A, et al. Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol 2009; 60:59-62.
12. Marks S, Varma R, Cantrell W, et al. Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis. J Eur Acad Dermatol Venereol 2009; 23:42-45.
13. Vlachou C, Kanelleas AI, Martin-Clavijo A, et al. Treatment of disseminated superficial actinic porokeratosis with topical diclofenac gel: a case series. J Eur Acad Dermatol Venereol 2008; 22:1343-1345.
14. Mastrolonardo M. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatol 2009; 34:33-35.
15. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol 2008; 7:669-673.
16. Iraji F, Siadat AH, Asilian A, etal. The safety of diclofenac for the management and treatment of actinic keratoses. Exp Opin Drug Safety 2008; 7:167-172.
17. Kose O, Koc E, Erbil AH, et al. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatol Treat 2008; 19:159-163.
18. Kuflik EG. Cryosurgery updated. J Am Acad Dermatol 1994; 31:925-934.
19. Iyer S, Friedli A, Bowes L, et al. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and nonmelanoma skin cancer. Lasers Surg Med 2004; 34:114-119.
20. Coleman WP, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg 1996; 22:17-21.
21. Stritt A, Merk HF, Braathen LR, etal. Photodynamic therapy in the treatment of actinic keratosis. Photochem Photobiol 2008; 84:388-398.
22. Pariser D, Loss R, Jarratt M. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008; 59:569-576.
23. Wiegell SR, Haedersdal M, Philipsen PA, etal. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses: a randomized, controlled, single-blinded study. Br J Dermatol 2008; 158:740-746.
24. Paoli J, Halldin C, Ericson MB, etal. Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses. Clin Exp Dermatol 2008; 33:559-564.
25. Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges 2008; 6:664-677.
26. Gill D, Dorevitch A, Marks R. The prevalence of seborrheic keratoses in people aged 15 to 30 years: is the term senile keratosis redundant? Arch Dermatol 2000; 136:759-762.
27. Rohwedder A, Foong H, Tyring SK, et al. Incidental epidermodysplasia verruciformis human papillomavirus infection (EV acanthoma): evidence for 'field cancerization? and a putative cofactor in seborrheic keratosis. J Cut Pathol 2008; 35:1151-1155.
28. Ko CJ, Iftner T, Barr RJ, Binder SW. Changes of epidermodysplasia verruciformis in benign skin lesions: the EV acanthoma. J Cut Pathol 2007; 34:44.
29. Braga JC, Scope A, Klaz I, et al. Melanoma mimicking seborrheic keratosis: an error of perception precluding correct dermoscopic diagnosis. J Am Acad Dermatol 2008; 58:875-880.
30. Fink AM, FilzD, KrajnikG, etal. Seborrhoeic keratoses in patients with internal malignancies: a case-control study with prospective accrual of patients. J Eur Acad Dermatol Venereol 2009. [Epub ahead of print]
31. Kilmer SL. Laser eradication of pigmented lesions and tattoos. Dermatol Clin 2002; 20:37-53.
32. Culbertson GR. 532-nm diode laser treatment of seborrheic keratoses with color enhancement. Dermatol Surg 2008; 34:525-528.
33. Gollnick H, Layton A. Azelaic acid 15% gel in the treatment of rosacea. Exp Opin Pharmacother 2008; 9:2699-2706.
34. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46:584-587.
35. Marks R. The enigma of rosacea. J Dermatol Treat 2007; 18:326-328.
36. Aroni K, Tsagroni E, Kavantzas N, et al. A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res 2008; 300:125-131.
37. Jappe U, Schäfer T, Schnuch A, et al. Contact allergy in patients with rosacea: a clinic-based, prospective epidemiological study. J Eur Acad Dermatol Venereol 2008; 22:1208-1214.
38. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008; 47:284-288.
39. Del Rosso JQ, Baldwin H, Webster G, American Acne & Rosacea Society. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol 2008; 7:531-533.
40. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100mg in the treatment of rosacea. J Drugs Dermatol 2008; 7:573-576.
41. Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, et al. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol 2008; 7:541-546.
42. Van Zuuren EJ, Gupta AK, Gover MD, et al. Systematic review of rosacea treatments. J Am Acad Dermatol 2007; 56:107-115.
43. KarabulutAA, Izol Serel B, Eksioglu HM. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. J Eur Acad Dermatol Venereol 2008; 22:729-734.
44. Lee DH, Li K, Suh DH. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. Br J Dermatol 2008; 158:1069-1076.
45. Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol 2008; 159:628-632.
46. Bernstein EF, Kligman A. Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser. Lasers Surg Med 2008; 40:233-239.